2 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow ERBB2 Gene Mutation: new trials by email Literature Review of ERBB2 Gene Mutation trials Research Report on ERBB2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Poziotinib - EGFR Exon 20 Mutation, ERBB2 Gene Mutation | Phase 2 | Terminated | M.D. Anderson Cancer Center | 93 | 2017-03-17 | 2026-02-20 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasm Metastasis (1)
Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Everolimus (1) · HM781-36B (1) · neratinib (1) · palbociclib (1) · trametinib (1)
M.D. Anderson Cancer Center (2)
United States (2)
Sarina A Piha-Paul (1) · Yasir Y Elamin (1)